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This pilot study examined the efficacy of eye movement desensitization and reprocessing (EMDR) treat-
ment compared with cognitive behavioral therapy (CBT) in treating posttraumatic stress disorder (PTSD) 
in oncology patients in the follow-up phase of the disease. The secondary aim of this study was to assess 
whether EMDR treatment has a different impact on PTSD in the active treatment or during the follow-
up stages of disease. Twenty-one patients in follow-up care were randomly assigned to EMDR or CBT 
groups, and 10 patients in the active treatment phase were assigned to EMDR group. The Impact of Event 
Scale—Revised (IES-R) and Clinician-Administered PTSD Scale (CAPS) were used to assess PTSD at 
pretreatment and 1 month posttreatment. Anxiety, depression, and psychophysiological symptoms were 
also evaluated. For cancer patients in the follow-up stage, the absence of PTSD after the treatment was 
associated with a significantly higher likelihood of receiving EMDR rather than CBT. EMDR was signifi-
cantly more effective than CBT in reducing scores on the IES-R and the CAPS intrusive symptom sub-
scale, whereas anxiety and depression improved equally in both treatment groups. Furthermore, EMDR 
showed the same efficacy both in the active cancer treatment and during the follow-up of the disease.
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R esearch exploring stress or trauma-related symptoms among cancer patients is not new (Andersen, Kiecolt-Glaser, & Glaser, 
1994; Butler, Koopman, Classen, & Spiegel, 1999; 
 Mehnert & Koch, 2007). However, the classifica-
tion of the types of stress related to these patients 
has been the focus of research over these last years. 
 Numerous studies in the literature have proposed 
that this population experiences stresses related to 
the  diagnosis of the  disease, and/or to the challenges 
of living with the illness that are much like how sur-
vivors of violent crime or natural disasters relate to 
their traumatic experiences ( Cordova, Studts, Hann, 
Jacobsen, &  Andrykowski, 2000; Jackson et al., 2007). 
Posttraumatic stress disorder (PTSD), which has been 
commonly associated with survivors of situations like 
those mentioned, is now being documented in cancer 
patients (Bruce, 2006; DuHamel et al., 2004).
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Society for Traumatic Stress Studies (Chemtob, Tolin, 
van der Kolk, & Pitman, 2000) and, in 2001, was 
indicated as an effective intervention for PTSD (classi-
fication A/B) by the United Kingdom Department of  
Health (Bisson et al., 2007; Onofri, 2012). It has been 
used throughout the world since 1990 and has proven 
to be effective for patients with a wide range of  stress 
and trauma-related diagnoses, including PTSD.
EMDR was effectively used with patients suffering 
from various diseases such as chronic pain (Grant & 
Threlfo, 2002; Schneider, Hofmann, Rost, & Shapiro, 
2008), fibromyalgia (Friedberg, 2004), and myocardial 
infarction (Arabia, Manca, & Solomon, 2011).
In particular, a recent pilot study found preliminary 
evidence that EMDR was more effective than imagi-
nal exposure therapy in the treatment of  patients who 
had survived a life-threatening cardiac event (Arabia 
et al., 2011). This pilot study is the first structured re-
search project in Italy, using CBT and EMDR in cancer 
patients, treated at the Regina Elena National Cancer 
Institute in Rome, Italy.
There are two prevalent assumptions in the 
psycho- oncology literature regarding the individual’s 
response to his or her illness: the first views the per-
son with cancer as being interconnected to a series 
of  crises that occur over the course of  the illness and 
that involve changes in the environmental ecosystem 
surrounding the patient (Morasso, 2002). The second 
focuses more on the individual and sees him or her as 
vulnerable or as having a psychopathological predis-
position (Morasso, 2002). The focus on a “condition 
of  crises” risks a superficial appreciation of  psycho- 
oncological disease, missing both the traumatic 
impact of  the experience as well as the psychological 
malaise attached to cancer, experienced as “traumat-
ic” in such a way as to lead to a possible diagnosis of  
PTSD; a disturbance that is at the core of  the indi-
vidual’s psychopathology.
Cancer has qualities that are objectively traumatic 
(Castrogiovanni & Traverso, 2006). The following 
DSM-IV-TR classifications demonstrate the scientific 
community’s recognition of  the disease’s strong trau-
matizing impact on the individual.
•	 It	produces	a	sense	of 	threat	to	the	individual’s	life,	
to the quality of  life and the psychophysical integ-
rity of  the individual and others, including his or 
her family (Criterion A1 for PTSD, DSM-IV-TR; 
American Psychiatric Association, 2000).
•	 It	creates	an	oppressive	sense	of 	vulnerability,	loss	
of  control, and sense of  impotence (Criterion 
A2 for PTSD, DSM-IV-TR; American Psychiatric 
 Association, 2000).
PTSD is a disturbance defined by the development 
of  certain symptoms following an emotionally stress-
ful event that involved actual death or the threat of  
death, serious injury, or a threat to oneself  or  others 
(National Cancer Institute, 2012b). However, it is 
 important to note that until 1987, the third  revised 
edition of  the Diagnostic and Statistical Manual of  
Mental Disorders (DSM–III–R; American Psychiatric 
Association, 1987) excluded patients with medical ill-
nesses such as cancer from PTSD. Thanks to a text 
revision in the fourth edition of  the DSM (DSM-IV-TR) 
that took place in the year 2000 (American Psychiatric 
Association, 2000), the diagnostic criteria for PTSD, 
specifically includes “being diagnosed with a life-
threatening illness” as one example of  a traumatic 
event, and people with histories of  cancer can now be 
evaluated and considered at risk for PTSD (National 
Cancer Institute, 2012a).
There have been several studies of  PTSD in this 
population with a variety of  cancers—including 
melanoma, Hodgkin’s lymphoma, breast cancer, and 
mixed cancers—but they were not homogeneous in 
their assessment of  PTSD; some assessed patients for 
the full syndrome of  PTSD (i.e., all DSM-IV criteria 
met) or only some of  the PTSD-related symptoms 
(e.g., intrusive thoughts as measured by the Impact of  
Event Scale-Revised; IES-R; National Cancer Institute, 
2012a). It is important to note that PTSD is difficult to 
diagnose in any population for several reasons: first, 
because it can be confused with many other psycho-
logical disorders, and secondly, because the onset of  
symptoms can occur over time, in some cases many 
years after the traumatic experience. In reference to 
cancer patients, in a specific phase of  the oncological 
disease, symptoms can remain just below the surface, 
and even if  treated, can result in only a partial remis-
sion. A recent study undertaken by Duke Cancer 
Institute is one of  the few studies done to date that 
provides valuable data after a significant follow-up 
 period; the study documents PTSD in non-Hodgkin’s 
lymphoma patients over a median follow-up period 
of  12.9 years (Smith et al., 2011). In fact, this study 
demonstrated that PTSD actually intensified over the 
years. No single therapeutic strategy has been devel-
oped specifically for PTSD in this population. The 
literature on PTSD, however, is rich with examples 
of  many successful psychological therapies, including 
cognitive behavioral therapy (CBT) as has been doc-
umented internationally (Foa, Keane, Friedman, & 
Cohen, 2008; Rothbaum, Astin, & Marsteller, 2005; 
Taylor et al., 2003) and eye movement desensitiza-
tion and reprocessing (EMDR; Shapiro, 1995, 2001). 
EMDR has been recognized by the International 
136 Journal of EMDR Practice and Research, Volume 7, Number 3, 2013
 Capezzani et al.
were in a follow-up phase. The 21 patients in the follow-
up care of  the disease were randomly assigned to one 
of  two treatment groups: EMDR or CBT. The patients 
in the treatment phase (n 5 10) were assigned to the 
EMDR treatment only study. As a result, we have three 
groups of  patients: one group of  patients in the treat-
ment phase undergoing EMDR only (n 5 10), one group 
of   patients in the follow-up stage study  undergoing 
EMDR (n 5 11), and the other group of   patients in the 
follow-up stage undergoing CBT (n 5 10).
Measures
All of  the questionnaires used for the assessment of  
participants in the study are self-administered except for 
the Clinical-Administered PTSD Scale (CAPS), which 
was administered by a blind independent interviewer.
The Clinician-Administered PTSD Scale (CAPS). 
The CAPS (Blake et al., 1995), in its Current and Life-
time Diagnostic Version (DX version) is a clinical sem-
istructured interview based on the DSM-IV-TR, which 
is the gold standard to assess PTSD (Foa & Tolin, 2000; 
Weathers, Keane, & Davidson, 2001). The structure 
corresponds to the DSM-IV criteria, with B (intrusion), 
C (avoidance), and D (hyperarousal) symptoms rated 
for both frequency and intensity; these two scores are 
summed to provide severity ratings. Additional ques-
tions assess Criteria A, E, and F.
The Impact of  Event Scale—Revised (IES-R). The 
IES-R (Weiss & Marmar, 1997) is a 22-item question-
naire consisting of  three subscales (intrusion, avoid-
ance, and hyperarousal) that assesses subjective 
distress caused by traumatic events. Respondents are 
asked to identify a specific stressful life event and then 
indicate how much they were distressed or bothered 
during the past seven days by each “difficulty” listed.
The Psychophysiological Questionnaire—Brief Version 
(QPF-R). The QPF-R (Pancheri, Chiari, &  Michielin, 
1985) was used to evaluate psychophysiological  reactions. 
It includes 30 items on a 0–4 Likert scale that refers to 
 somatic symptoms without  demonstrable  organic base.
The State-Trait Anxiety Inventory (STAI-Y). The 
STAI-Y (Spielberger, Gorsuch, & Lushene, 1970) 
is used to evaluate state anxiety (STAI-1) and trait 
 anxiety (STAI-2). It encompasses 40 questions, 20 for 
state anxiety and 20 for trait anxiety. Each item is eval-
uated according to a 0–4 Likert scale.
The Beck Depression Inventory-II (BDI). The BDI 
(Beck & Steer, 1993) is a 21-item self-report instru-
ment that assesses the presence and severity of  symp-
toms consistent with the criteria of  the DSM-IV.
•	 Strong	 emotional	 reactions	 are	 exhibited	 with	
intrusive thoughts, avoidance of  daily behaviors, 
elevated arousal, both in an acute form and chronic 
form that interfere with normal capacity to func-
tion (Criteria B, C, D, and F for PTSD, DSM-IV-TR; 
American Psychiatric Association, 2000).
As cited in the DSM-IV-TR (American Psychiatric 
 Association, 2000), under criterion “E” of  PTSD, 
symptoms must be present for at least 1 month, as 
might be the case following a cancer diagnosis.
Aims
The primary aim of  this pilot study was to evaluate the 
relative efficacy of  EMDR treatment compared with 
CBT in oncology patients with PTSD in the follow-up 
phase of  the disease. We sought to evaluate the rela-
tive efficacy of  EMDR and CBT on specific measures 
of  PTSD as well as on PTSD-associated symptoms 
of  anxiety, depression, and psychophysiological reac-
tions. The secondary aim of  this study was to assess 
whether EMDR treatment has a different impact on 
PTSD and PTSD symptoms in two different stages 
of  disease (active treatment of  cancer vs. follow-up) 
to address the question of  whether EMDR treatment 
can produce benefits for cancer patients in the earlier 
phases of  their medical treatment.
Methods
Participants
Thirty-one patients with different types of  cancer 
(breast, colon, uterus, thyroid, melanoma, lung, 
and stomach cancer) were consecutively recruited 
from May 2010 to June 2012 from the Departments 
of   Digestive Surgery, Thoracic Surgery, and Medi-
cal  Oncology (Department B) of  the Regina Elena 
 National Cancer Institute in Rome, Italy. The patients 
were recruited by including all the referrals to the 
psychiatric clinic made by the Oncology Units who 
satisfied the clinical diagnosis of  PTSD (31 out of  
623 patients, 4.97%). All 31 patients agreed to partici-
pate in the study.
Inclusion criteria were as follows: (a) DSM-IV 
diagnostic criteria for PTSD and (b) absence of  psy-
chopharmacological therapy.
Exclusion criteria were as follows: (a) patients 
already in psychotherapy and (b) patients with psycho-
pathological disturbances preexisting to the cancer 
diagnosis.
Patients were placed into one of  two studies 
 depending on the stage of  the disease: 10 patients were 
in an active cancer treatment phase and 21  patients 
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about the future). All eight phases of  EMDR were 
followed (Shapiro, 2001) and the treatment focused 
only on the oncological disease and did not address 
any previous traumatic events.
3. Integration: reduction of  distress and increased 
resources were integrated in the daily life in order 
to increase the patients’ adjustment to being a 
 cancer survivor.
All EMDR treatments were provided by a psycho-
therapist with 10 years of  clinical experience in using 
EMDR.
CBT. The following techniques or therapeutic ap-
proaches were used according to the PTSD symptoms 
that were most frequently reported by each  patient 
and according to the phase of  psychotherapy. The 
goals to be achieved were as follows:
1. To stabilize the initial symptoms of  the patient. For 
hyperarousal: psychoeducation, Rational Emotive 
Imagery (REI; Ellis, 1994), a technique of  guided 
visualization, gradual and/or prolonged exposure 
to stressor in vivo or by visual imagination, and 
progressive relaxation techniques with instruction 
regarding diaphragmatic breathing for treatment 
of  insomnia. For hypoarousal: psychoeducation, 
instructions to homework defining and recogniz-
ing and activating somatic resources (e.g., a struc-
tured physical activity program; Beck, Rush, Shaw, 
& Emery, 1979).
2. For flashback and intrusive thoughts: shifting of  
attention techniques.
3. For avoidance or escape behaviors: systematic 
desensitizing and gradual exposure by visual imag-
ination or in vivo exposure (people or things).
4. For cognitive restructuring of  negative  cognitive 
thoughts related to the traumatic experience: 
forms A, B, C, D, E of  Rational Emotive Behavior 
Therapy (REBT; Ellis, 1994) and socratic dialogue.
5. For the monitoring of  psychophysiological fluc-
tuation and the maintenance of  new behavioral 
 patterns: homework and diary entries.
6. For therapeutic compliance: monitoring  techniques 
and redefinition of  therapeutic alliances.
All the CBT treatments were provided by the 
same psychotherapist who provided the EMDR 
treatment and with 12 years of  clinical experience in 
using CBT.
Statistical Analyses
Data were processed and analyzed using the Statis-
tical Package for Social Sciences (SPSS) version 17.0 
( Chicago, IL, USA).
Procedure
Assessment. Assessments were conducted at pre-
treatment and 1 month after the end of  the treatment 
sessions.
Patients arrived at the center by referral from a 
physician within the hospital or from a general prac-
titioner for the first interview. When the psychologist 
(LC) noticed clinical cues for a PTSD diagnosis, she 
invited patients to meet an independent and blind 
assessor who administered the CAPS in order to in-
vestigate the possible presence of  PTSD. Assessments 
included the clinician interview of  patient’s medical 
history, which was carried out by the treating clini-
cian during pretreatment and posttreatment. Then, 
patients with a confirmed diagnosis of  PTSD were 
asked to complete the other psychological self-report 
questionnaires given to the patients by an indepen-
dent assessor who was also available for answering 
questions about compiling the questionnaires. Then 
they were invited to participate in the research pro-
tocol. If  they agreed, they discussed and signed the 
informed consent.
If  they were in the follow-up phase of  the disease, 
they were randomized to the EMDR treatment or to 
the CBT treatment. If  they were in the active treat-
ment phase of  the disease, they were assigned only to 
the EMDR treatment.
Treatment. All the participants, regardless of  the 
type of  treatment  received and of  the stage of  the dis-
ease, received 8 weekly treatment sessions. Following 
completion of  treatment, all patients with symptoms 
still present after 1 month were advised to continue 
psychotherapy with the treatment provider despite 
the conclusion of  the study.
EMDR. The EMDR standard protocol (Shapiro, 2001) 
of  eight stages was administered, with the goal of  
achieving the following:
1. Stabilization by psychoeducation (on emotional 
adaptation to cancer, PTSD features, and EMDR 
treatment) and “resource installation” (Shapiro, 
2001) including the “safe place” (Shapiro, 2001) 
technique in order to stabilize the clients and pre-
pare them for treatment.
2. Identification and reprocessing of  disturbing 
memories related to the oncological disease in all 
three prongs of  the EMDR protocol: present and 
past events, identified through history taking and 
float back (e.g., diagnosis and relapse communica-
tions, treatment complications, and side effects) 
and in future templates for handling worries and 
fears (e.g., worsening of  physical functioning, fear 
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EMDR treatment has a different impact depending on 
the stage of  disease in which it is carried out.
A p , .05 was considered statistically significant 
throughout all of  the analyses.
Results
There were 31 patients enrolled in the study: 10 of  
them were in an active cancer treatment phase, all 
treated with EMDR and the other 21 patients were 
in a follow-up phase, of  which 11 patients were ran-
domized to the EMDR treatment and 10 patients 
were randomized to the CBT treatment. We did not 
have any patient dropouts from the treatment.  Results 
showed that the different types of  cancer (breast, 
colon, uterus, thyroid, melanoma, lung, and stomach 
cancer) were balanced in the three groups.
Comparison Between EMDR and CBT 
Treatments in the Follow-up Phase of the 
Cancer Disease
There were 21 patients in a follow-up phase, of  
which 11 were randomized to the EMDR treatment 
(all  females) and 10 patients were randomized to the 
CBT treatment (8 females and 2 males). The mean 
age of  the patients was similar in both groups (52.70, 
SD 5 8.68 for CBT and 50.82, SD 5 7.64 for EMDR). 
There were no differences in clinical variables  between 
the two groups at baseline (see Table 1).
Baseline group differences were assessed using 
one-way analysis of  variance (ANOVA) to compare 
the three groups for continuous measures and Fisher’s 
Exact Test for categorical measures.
Fisher’s Exact Test was also used to evaluate the 
association between the treatment group (EMDR vs. 
CBT) and the PTSD diagnosis at time T1.
Generalized linear model (GLM) repeated mea-
sures multivariate ANOVA (RM-MANOVA) was used 
to analyze the main preintervention and postinterven-
tion effects and interactions both between and within 
EMDR and CBT groups in the follow-up phase of  
disease. Pairwise comparison between groups were 
made by simple contrast and are reported as means 
difference with the Sidak correction 95% confidence 
interval (95% CI) for multiple comparisons.
Simple logistic regression analyses were computed 
by taking the presence of  PTSD after the treatment 
as a dichotomous dependent variable, and by consid-
ering singularly as independent variables age, gender, 
treatment type (EMDR vs. CBT), and the clinical 
variables scores at baseline (QPF-R, STAI-1, STAI-2, 
BDI-II, IES-R Total, CAPS Criterion B, C, and D) for 
patients who were in the cancer follow-up phase.
As a secondary outcome, RM-MANOVA was used 
to analyze the main preintervention and postinterven-
tion effects and interactions both between and within 
the different cancer treatment phase groups (active 
treatment vs. follow-up) in order to evaluate whether 
TABLE 1. Clinical Data of Participants in the Follow-up Phase of the Cancer Disease
Pretreatment Posttreatment
Sig.
CBT  
(N 5 10)
EMDR  
(N 5 11)
CBT 
(N 5 10)
EMDR  
(N 5 11)
QPF-R 61.60 (15.71) 57.45 (13.55) 54.50 (13.24) 48.45 (12.18) *
STAI-1 45.40 (4.95) 44.73 (5.42) 43.90 (5.55) 40.00 (3.41) *
STAI-2 46.50 (5.34) 45.82 (6.15) 43.80 (4.10) 43.55 (5.70)
BDI-II 26.30 (8.73) 25.73 (10.89) 20.10 (9.24) 14.45 (9.30) *
IES-R total 54.70 (10.62) 50.91 (9.45) 46.60 (14.13) 20.55 (17.85) *, §
CAPS Criterion B 20.90 (7.71) 19.55 (8.15) 15.30 (5.87) 6.18 (6.95) *, §
CAPS Criterion C 30.30 (8.13) 28.36 (12.19) 20.50 (7.59) 10.45 (7.54) *
CAPS Criterion D 27.60 (6.22) 24.00 (8.15) 16.20 (9.16) 9.91 (5.61) *
Note. Data are mean (SD). QPF-R 5 Psychophysiological Questionnaire—Brief  Version; STAI-1 5 State-Trait Anxiety Inventory—state 
anxiety; STAI-2 5 State-Trait Anxiety Inventory—trait anxiety; BDI-II 5 Beck Depression Inventory-II; IES-R total 5 Impact of  Event 
Scale—Revised total score; CAPS Criterion B 5 Clinician-Administered PTSD Scale—intrusion symptoms; CAPS Criterion C 5 Clinician-
Administered PTSD Scale—avoidance symptoms; CAPS Criterion D 5 Clinician-Administered PTSD Scale—hyperarousal symptoms.
* significant pre–post effect, independent of  the type of  treatment (CBT or EMDR).
§ significant group (CBT vs. EMDR)-by-time (pretreatment vs. posttreatment) interaction effects.
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measures and the treatment condition (F[8, 12] 5 
4.855, p 5 .007; h
p
2 5 .764).
Significant time effects were found across both 
groups on all variables except for STAI-2 (trait anxi-
ety), indicating that the mean participant scores 
improved from time 0 (preintervention) to time 1 
(postintervention; see Table 1).
Group-by-time interaction effects were found for 
the IES-R total scores (F[1, 19] 5 14.041, p , .001; 
see Figure 1) and for the CAPS Criterion B scores 
(F[1, 19] 5 7.584, p 5 .013; see Table 1 and Figure 2). 
No group-by-time interactions were found for the 
We evaluated whether the different psychothera-
py treatments (EMDR or CBT) administered to the 
patients during their cancer follow-up phase had a 
different impact on the psychological variables of  in-
terests. A repeated measures MANOVA was performed 
on the preintervention and postintervention clinical 
scores (QPF-R, STAI-1, STAI-2, BDI-II, IES-R Total, 
CAPS Criterion B, C, and D) comparing group and 
time effects and interactions between group and time.
The RM-MANOVA yielded a significant pre–post 
main effect (F[8, 12] 5 13.547, p , .001; hp
2 5 .900) 
and a significant interaction between the pre–post 
FIGURE 1. Interaction between time and treatment for IES-R total score.
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FIGURE 2. Interaction between time and treatment for CAPS Criterion B score.
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(EMDR vs. CBT; R2 5 .71; OR 5 0.011, CI 95% 
[0.001, 20.205]; p 5 .002). The contribution of  the 
other demographical and clinical variables did not 
reach statistical significance. The absence of  PTSD 
after the treatment was associated with a higher likeli-
hood of  having undergone an EMDR psychotherapy 
treatment. Specifically, 10 out of  11 patients treated 
with EMDR did not have PTSD after the treatment, 
whereas 9 of  10 patients treated with CBT maintained 
a PTSD diagnosis at the postintervention evaluation 
(Fisher’s Exact Test; p , .001, h
p
2 5 .809).
Efficacy of EMDR Treatment in the Two 
Different Stages of Disease (Active Treatment 
of Cancer vs. Follow-up)
As a secondary aim, we evaluated also whether 
EMDR treatment has a different impact depending 
on whether patients were in active treatment for their 
cancer or whether they were in follow-up care.
The 21 patients were divided as follows: 10 of  
them were in an active cancer treatment phase 
(9  females and 1 male), whereas the other 11 were 
in a follow-up phase (all females). The mean age of  
the patients was similar in both groups (53.40, SD 5 
8.59 for the patients in the active treatment phase 
and 50.82, SD 5 7.64 for the patients in the follow-up 
phase). There were no differences in clinical variables 
between the two groups at baseline (see Table 2).
The RM-MANOVA yielded a significant pre–post 
main effect (F[8, 12] 5 22.900, p , .001; hp
2 5 .939), 
whereas no significant interaction was found between 
the pre–post measures and the different cancer treat-
ment phase (active treatment vs. follow-up) condition 
(F[8, 12] 5 .885, p 5 .555; h
p
2 5 .371). Significant 
time effects were found across both groups on all 
variables except for STAI-2 (trait anxiety), indicating 
that regardless of  the stage of  disease group, scores 
improved from Time 0 (preintervention) to Time 1 
(postintervention). Therefore, the EMDR treatment 
can be considered effective regardless of  the stage of  
disease.
Almost all the patients (20 out of  21, 95.2%) did not 
have PTSD after the EMDR treatment.
Discussion
Efficacy of EMDR Treatment Compared 
With CBT in the Follow-up Phase of the  
Cancer Disease
The most significant result emerging from this study 
is that most patients in the cancer follow-up phase 
treated with EMDR were able to overcome their 
QPF-R, STAI-1, BDI-II, IES-R, CAPS-C, and CAPS-D, 
indicating that changes on these measures were simi-
lar for both treatment groups.
Planned post hoc analyses of simple effects of pre–
post were conducted for the IES-R by GLM pairwise 
comparisons using the Sidak adjustment for multiple 
comparisons (see Figure 1). Results indicated that the 
IES-R total score at posttreatment (M 5 20.56, SE 5 
4.880) was significantly lower than the pretreatment 
score for the EMDR group (M 5 50.91, SE 5 3.020), 
mean difference 5 230.364 (95% CI [238.945, 
221.782]), p , .001. There was no difference 
 between the posttreatment (M 5 46.60, SE 5 5.12) 
and pretreatment scores (M 5 17.73, SE 5 1.497) for 
participants who had received CBT treatment, mean 
difference 5 28.100 (95% CI [217.100, 0.900]), p 5 
.075. This indicates that the improvements over time 
were significantly greater in the EMDR treatment 
group than in the CBT group (see Figure 1).
The analysis of  simple effects reveals also a 
significant difference between EMDR and CBT post-
treatment IES-R scores: the IES-R scores of  the 
EMDR group (M 5 20.55, SE 5 4.88) are signifi-
cantly  lower than the scores of  the CBT group 
(M 5 46.60, SE 5 5.12), mean difference 5 226.055 
(95% CI [240.865, 211.244]), p 5 .002.
Planned post hoc analyses of  simple effects were 
also conducted for the CAPS intrusion subscale (see 
Figure 2). The analysis of  simple effects indicated that 
the Criterion B score at posttreatment (M 5 6.18, 
SE 5 1.95) was significantly lower than the pretreat-
ment score for the EMDR group (M 5 19.56, SE 5 
2.40), mean difference 5 213.364 (95% CI [217.435, 
29.292]), p , .001. There was also a difference be-
tween the posttreatment (M 5 15.30, SE 5 2.04) 
and pretreatment scores (M 5 20.90, SE 5 2.51) for 
participants who had received CBT treatment, mean 
difference 5 25.600 (95% CI [29.870, 21.330]), 
p 5 .013.
Although both groups had an improvement in 
 intrusive symptoms, the comparison between CAPS 
Criterion B posttreatment scores showed that the 
EMDR group scored significantly lower (M 5 6.18, 
SE 5 1.95) as compared to the CBT group (M 5 
15.30, SE 5 5.04), mean difference 5 29.118 (95% CI 
[215.029, 23.207]), p 5 .004.
Furthermore, a binary logistic regression analysis 
was performed in order to detect the possible influ-
ence of  the treatment type (EMDR vs. CBT) and the 
influence of  the clinical variables to the presence of  
PTSD after the treatment sessions. It was showed 
that the presence of  PTSD after the treatment was 
significantly associated only with the treatment type 
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Limitations and Conclusions
The study also has several limitations. The number of  
 included patients treated with CBT or EMDR is not large.
Another limitation is that there were no fidelity 
checks on the treatment sessions. Finally, all patients 
in each group received their treatment from only one 
therapist giving rise to the possibility that the  differences 
could be because of  differences in clinical skills with non-
specific treatment variables such as the  development of  
therapeutic alliance or other factors.
Future research could be designed to address some 
of  the research questions not fully answered in this 
study and correcting the limitations of  this study, for 
example, should include a greater number of  patients 
treated and should involve more therapists in each 
treatment group. Future studies should also include 
treatment fidelity checks. Finally, they should pro-
vide for a follow-up of  at least 6 months after the end 
of  treatment to show the stability of  the treatment 
 effects across the different conditions.
Although our results can only be considered prelim-
inary, this pilot study suggests that in cancer patients 
undergoing follow-up care, EMDR had an advan-
tage over CBT in eliminating the diagnosis of  PTSD. 
EMDR was significantly more effective than CBT in 
reducing scores on the IES-R and the CAPS intrusive 
symptom subscale, whereas both psychotherapies 
appear to be equally effective on trait anxiety, depres-
sion, and psychophysiological reactions.
PTSD  diagnosis after eight therapy sessions; on the 
contrary,  almost all patients in the same stage of  dis-
ease but treated with CBT still had a diagnosis of  
PTSD 1 month after the end of  the psychotherapeutic 
treatment.
EMDR treatment significantly reduced symptoms 
of  posttraumatic stress measured with the IES-R 
 total score whereas CBT did not have this effect. The 
 intrusive symptoms as measured by Criterion B of  
the CAPS reduced significantly both for patients treat-
ed with EMDR and with CBT, although in the group 
treated with EMDR, there is a greater decrease. The 
group of  patients treated with EMDR had both lower 
IES-R and CAPS intrusive symptom subscale scores 
after the psychological treatment compared with the 
group of  patients treated with CBT.
Anxiety, depression, and psychophysiological reac-
tions improved in both groups, showing that both 
types of  psychotherapy are effective on these symp-
toms in a limited number of  sessions.
Efficacy of EMDR Treatment in the Two 
Different Stages of Disease (Active Treatment 
of Cancer vs. Follow-up)
EMDR treatment was effective both in the phase of  
 active cancer treatment and during the follow-up of  
the disease. All patients showed a clinical improvement 
regarding PTSD, anxiety, depression, and psycho-
physiological reactions.
TABLE 2. Clinical Variables of the Groups Treated With EMDR at Pre and Posttreatment
Pretreatment Posttreatment
Sig.
Active Cancer 
Treatment  
(N 5 10)
Follow-up Cancer 
Treatment  
(N 5 11)
Active Cancer 
Treatment  
(N 5 10)
Follow-up Cancer 
Treatment  
(N 5 11)
QPF-R 58.50 (9.70) 57.45 (13.55) 48.30 (9.65) 48.45 (12.18) *
STAI-1 43.70 (3.37) 44.73 (5.42) 42.70 (3.50) 40.00 (3.41) *
STAI-2 46.10 (5.65) 45.82 (6.15) 43.30 (4.55) 43.55 (5.70)
BDI-II 27.00 (7.70) 25.73 (10.89) 15.50 (8.33) 14.45 (9.30) *
IES-R total 48.50 (14.74) 50.91 (9.45) 28.60 (9.38) 20.55 (17.85) *
CAPS Criterion B 20.70 (6.82) 19.55 (8.15) 6.20 (3.08) 6.18 (6.95) *
CAPS Criterion C 22.50 (4.09) 28.36 (12.19) 7.40 (3.89) 10.45 (7.54) *
CAPS Criterion D 19.90 (9.25) 24.00 (8.15) 6.60 (4.22) 9.91 (5.61) *
Note. Data are mean (SD) or N (%). QPF-R 5 Psychophysiological Questionnaire—Brief  Version; STAI-1 5 State-Trait Anxiety Inventory—
state anxiety; STAI-2 5 State-Trait Anxiety Inventory—trait anxiety; BDI-II 5 Beck Depression Inventory-II; IES-R total 5 Impact of  Event 
Scale—Revised total score; CAPS Criterion B 5 Clinician-Administered PTSD Scale—intrusion symptoms; CAPS Criterion C 5 Clinician-
Administered PTSD Scale—avoidance symptoms; CAPS Criterion D 5 Clinician-Administered PTSD Scale—hyperarousal symptoms.
* significant pre–post effect, independent of  the phase of  the disease (active treatment vs. follow-up)
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from the International Society for Traumatic Stress Studies 
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symptom scale-interview version and the Clinician- 
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Friedberg, F. (2004). Eye movement desensitization in 
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Grant, M., & Threlfo, C. (2002). EMDR in the treatment of  
chronic pain. Journal of  Clinical Psychology, 58, 1505–1520.
Jackson, J. C., Hart, R. P., Gordon, S. M., Hopkins, R. O., 
Girard, T. D., & Ely, E. W. (2007). Post-traumatic stress 
disorder and post-traumatic stress symptoms following 
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post-traumatic stress disorder and comorbid mental dis-
orders in breast cancer patients during primary cancer 
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Our study suggests that EMDR could be a viable 
therapy for cancer patients with a PTSD diagnosis 
both in an active treatment phase and in follow-up.
These positive results in both treatment condi-
tions show that it is of  crucial importance that cancer 
patients have access to psychological support and 
to specific treatments that have been shown to be 
effective, to enable patients to manage the many dif-
ficulties of  adjustment to being a cancer survivor, and 
to help them begin a positive process of  psychological 
resilience.
Our data can contribute to a greater knowledge 
among medical practitioners in relation to psycho-
logical symptoms that may result from cancer disease, 
which could be precursors to a PTSD diagnosis. 
Having this information can lead to a prompt referral 
for psychotherapy.
As shown in this study, specific psychotherapy with 
EMDR and with CBT can be effective even with a lim-
ited number of  sessions. Future studies with a larger 
sample size are needed to confirm and extend the re-
sults of  this preliminary investigation.
To conclude, our study suggests that both EMDR 
and CBT therapies are effective in treating many psy-
chological symptoms in oncological patients, but our 
results suggest that EMDR could be a more effective 
therapy for cancer patients with a PTSD diagnosis, in 
particular for intrusive symptoms, both in an active 
treatment and in a follow-up stage of  the disease.
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